New patent expiration for Endo Ventures drug SUMAVEL DOSEPRO

Annual Drug Patent Expirations for SUMAVEL+DOSEPRO
Annual Drug Patent Expirations for SUMAVEL+DOSEPRO

Sumavel Dosepro is a drug marketed by Endo Ventures Ltd
and is included in one NDA. It is available from two suppliers. There are twelve patents protecting this drug.

This drug has one hundred and one patent family members in thirty-one countries.

The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. Two suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical drugs have the most drug patents in Australia?

This chart shows the drugs with the most patents in Australia.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

The companies with the greatest patent coverage in Australia are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Pfizer drug GEODON

Annual Drug Patent Expirations for GEODON
Annual Drug Patent Expirations for GEODON

Geodon is a drug marketed by Pfizer and Pfizer Inc
and is included in three NDAs. It is available from eleven suppliers. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in fifty-four countries.

The generic ingredient in GEODON is ziprasidone hydrochloride. Eleven suppliers are listed for this compound. Additional details are available on the ziprasidone hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharma companies have the most supplementary protection certificates?

This chart shows the drug companies with the most supplementary protection certificates (SPCs).

SPCs are used in European Union and select others to encourage pharmaceutical innovation by
compensating for the long time needed to obtain regulatory approval for drugs. SPCs
come into force only after the corresponding general patent expires, and normally have a maximum lifetime of 5 years.

The total combined duration of market exclusivity of a general patent and SPC cannot normally exceed 15 years, but a six-month extention
may be obtained by responding to a request for pediatric trials.

The pharma companies with the most SPCs are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Pfizer drug GEODON

Annual Drug Patent Expirations for GEODON
Annual Drug Patent Expirations for GEODON

Geodon is a drug marketed by Pfizer and Pfizer Inc
and is included in three NDAs. It is available from eleven suppliers. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in fifty-four countries.

The generic ingredient in GEODON is ziprasidone hydrochloride. Eleven suppliers are listed for this compound. Additional details are available on the ziprasidone hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharma companies have the most supplementary protection certificates?

This chart shows the drug companies with the most supplementary protection certificates (SPCs).

SPCs are used in European Union and select others to encourage pharmaceutical innovation by
compensating for the long time needed to obtain regulatory approval for drugs. SPCs
come into force only after the corresponding general patent expires, and normally have a maximum lifetime of 5 years.

The total combined duration of market exclusivity of a general patent and SPC cannot normally exceed 15 years, but a six-month extention
may be obtained by responding to a request for pediatric trials.

The pharma companies with the most SPCs are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Pharmacia And drug SOMAVERT

Annual Drug Patent Expirations for SOMAVERT
Annual Drug Patent Expirations for SOMAVERT

Somavert is a drug marketed by Pharmacia And Upjohn
and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has fifty patent family members in fifteen countries.

The generic ingredient in SOMAVERT is pegvisomant. One supplier is listed for this compound. Additional details are available on the pegvisomant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical drugs have the most drug patents in Germany?

This chart shows the drugs with the most patents in Germany.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

The companies with the greatest patent coverage in Germany are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

New patent expiration for Pharmacia And drug SOMAVERT

Annual Drug Patent Expirations for SOMAVERT
Annual Drug Patent Expirations for SOMAVERT

Somavert is a drug marketed by Pharmacia And Upjohn
and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has fifty patent family members in fifteen countries.

The generic ingredient in SOMAVERT is pegvisomant. One supplier is listed for this compound. Additional details are available on the pegvisomant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com

Which pharmaceutical drugs have the most drug patents in Germany?

This chart shows the drugs with the most patents in Germany.

Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

The companies with the greatest patent coverage in Germany are:

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com